✦ LIBER ✦

ORCHIECTOMY AND ORCHIECTOMY PLUS MITOMYCIN C FOR METASTATIC PROSTATE CANCER IN PATIENTS WITH POOR PROGNOSIS: THE FINAL RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH IN CANCER THERAPY GENITOURINARY GROUP TRIAL

✍ Scribed by de Reijke, THEO M.; Keuppens, Frans I.; Whelan, Peter; Kliment, Jan; Robinson, Mel R.G.; Rea, Lesley-Ann; Sylvester, Richard J.

Book ID: 123006667
Publisher: Lippincott Williams and Wilkins
Year: 1999
Tongue: English
Weight: 805 KB
Volume: 162
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(05)68191-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Orchiectomy versus goserelin and flutami

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–-genitourinary group study 30853

✍ D. W. W. Newling; L. Denis; K. Vermeylen; European Organization for Research; Tr 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 603 KB

Orchidectomy versus goserelin plus fluta

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853)

✍ F. Keuppens; P. Whelan; J. L. De Carneiro Moura; D. Newling; A. Bono; L. Denis; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

Fotemustine in patients with advanced ga

Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European organization for research and treatment of cancer, gastrointestinal tract cancer cooperative group)

✍ Ph. Rougier; C. Van Pottelsberghe; T. Kok; B. Paillot; T. Wagener; J. De Greve; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Short-term versus long-term addition of

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer

✍ J. G. M. Klijn; H. J. De Voogt; U. E. Studer; F. H. Schröder; R. Sylvester; M. D 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 471 KB 👁 3 views

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Prognosis in patients with sentinel node

Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection

✍ A. P. T. van der Ploeg; A. C. J. van Akkooi; P. Rutkowski; M. Cook; O. E. Nieweg 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB